Plain-English translation of NCT06054906 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether sintilimab, an immune-boosting medication, works better when combined with weekly chemotherapy in patients with advanced stomach cancer. Patients receive this combination treatment before surgery to shrink the tumor, then continue treatment after surgery. The goal is to see if this approach helps more patients achieve a complete response and survive longer.
Standard chemotherapy alone for advanced stomach cancer has limited success, and doctors are looking for ways to improve outcomes. This medication works by helping your immune system recognize and fight cancer cells, and researchers want to see if combining it with chemotherapy gives better results than chemotherapy alone.
You likely qualify if…
You likely don't qualify if…
You would receive 6 weeks of treatment before surgery: weekly chemotherapy injections and immune therapy infusions every 3 weeks. After surgery, you would receive another 6 weeks of the same treatment combination. Throughout and after treatment, you would have regular blood tests, scans every 3 months to check for recurrence, and follow-up visits for 5 years. The study team will closely monitor you for any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Huashan Hospital
Enrollment target
~50 participants
Started
October 2023
Primary completion
June 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2024.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.